Taysha Gene Therapies earnings release, May 6, 2026

Taysha Gene Therapies, Inc. (TSHA) · Form 8-K, Item 2.02 · Filed · SEC filing

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

Reaffirmed FDA alignment on

TSHA-102

BLA pathway, including pivotal trial design, endpoints and potential to submit for approval based on REVEAL pivotal trial

6-month interim analysis, following recent breakthrough therapy Type B meeting

Further advanced dosing in the REVEAL pivotal trial, with enrollment in the ASPIRE trial ongoing across multiple sites; on track to complete dosing in REVEAL and ASPIRE in Q2 2026

Maintained favorable tolerability profile with no treatment-related SAEs or DLTs in REVEAL

Phase 1/2 and REVEAL pivotal trials as of May 2026 data cutoff; plan to present longer-term safety and efficacy data from Part A of REVEAL Phase 1/2 trials in Q2 2026

Initiated

BLA-enabling

PPQ campaign for

TSHA-102 in April

2026; completion expected in Q4 2026

Conference call and webcast today at 8:30 AM ET

Dallas – May 6, 2026 – Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update.

“We continued to execute our clinical development strategy for

TSHA-102 and recently reaffirmed alignment with the FDA on our pathway to a BLA filing, including trial design, endpoints and the potential to submit for approval based on the six-month interim analysis from the REVEAL pivotal trial,” said Sean P. Nolan, Chairman and Chief Executive Officer of Taysha. “We further advanced dosing in the REVEAL pivotal trial, with enrollment in the ASPIRE trial ongoing across multiple sites, and we remain on track to complete dosing in both trials this quarter. In parallel, we plan to report longer-term safety and efficacy data from Part A of our REVEAL Phase 1/2 trials in the second quarter of this year.”

Mr. Nolan continued, “Our pivotal development strategy is grounded in the rigor of our natural history analysis and Part A data collection and evaluation, with trial design, endpoints and statistical analyses developed based on discussions with the FDA. In our upcoming Part A data readout, we expect to report longer-term follow-up, including at least

12-month data from all 12 pediatric, adolescent and adult patients treated with

TSHA-102.

These results will include functional gains based on natural history-defined developmental milestones and additional skills and improvements that impact activities of daily living. We look forward to sharing this data as we continue to demonstrate the differentiated opportunity for

TSHA-102 to deliver meaningful benefit to a broad population of patients with Rett syndrome who continue to face high unmet medical need.”

Recent Corporate and

TSHA-102

Program Highlights

Anticipated Milestones

First Quarter 2026 Financial Highlights

Research and Development Expenses:

Research and development expenses were $33.8 million for the three months ended March 31, 2026, compared to $15.6 million for the three months ended March 31, 2025. The $18.2 million increase was primarily driven by

BLA-enabling

PPQ manufacturing initiatives performed during the three months ended March 31, 2026, and higher clinical expenses from the REVEAL and ASPIRE trials. Compensation expenses, including non-cash stock-based compensation, also increased as a result of additional research and development headcount.

General and Administrative Expenses:

General and administrative expenses were $9.7 million for the three months ended March 31, 2026, compared to $8.2 million for the three months ended March 31, 2025. The increase of $1.5 million was primarily due to higher compensation expenses, including non-cash stock-based compensation expense, and increases in consulting and professional fees, including commercial launch-readiness initiatives.

Net Loss:

Net loss for the three months ended March 31,

2026, was $42.4 million, or $0.12 per share, compared to a net loss of $21.5 million, or $0.08 per share, for the three months ended March 31, 2025.

Cash and Cash Equivalents:

As of March 31, 2026, Taysha had $276.6 million in cash and cash equivalents. The Company expects that its current cash resources will be sufficient to fund planned operating expenses into 2028.

Conference Call and Webcast Information

Taysha management will host a live conference call and webcast today at 8:30 a.m. ET to review its financial and operating results and provide a corporate update. Participants may access the live webcast of the conference call by visiting Taysha’s website.

About

TSHA-102

TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome. Designed as a one-time treatment,

TSHA-102 aims to address the genetic root cause of the disease by delivering a functional form of

MECP2 to cells in the CNS.

TSHA-102 utilizes a novel miRNA-Responsive Auto-Regulatory Element (miRARE) technology designed to mediate levels of

MECP2 in the CNS on a cell-by-cell basis without risk of overexpression.

TSHA-102 has received Breakthrough

Therapy, Regenerative Medicine Advanced Therapy, Fast Track and Orphan Drug and Rare Pediatric Disease designations from the FDA, Orphan Drug designation from the European Commission and Innovative Licensing and Access

Pathway designation from the Medicines and Healthcare products Regulatory Agency.

About Rett Syndrome

Rett syndrome is a rare neurodevelopmental disorder caused by mutations in the

X-linked

MECP2 gene encoding methyl

CpG-binding... (truncated)rized by loss of communication and hand function, slowing and/or regression of development, motor and respiratory impairment, seizures, intellectual disabilities and shortened life expectancy. Rett syndrome progression is divided into four key stages, beginning with early onset stagnation at 6 to 18 months of age followed by rapid regression, plateau and late motor deterioration. Rett syndrome primarily occurs in females and is one of the most common genetic causes of severe intellectual disability. Currently, there are no approved disease-modifying therapies that treat the genetic root cause of the disease. Rett syndrome caused by a pathogenic/likely pathogenic

MECP2 mutation is estimated to affect between 15,000 and 20,000 patients in the U.S., EU, and U.K.

About Taysha Gene Therapies

Taysha Gene

Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program

TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit www.tayshagtx.com.

Financial statements

Income Statement

For the Three Months Ended March 31, — (in thousands, except share and per share data)

For the Three Months Ended March 31, – 2026For the Three Months Ended March 31, – 2025
Revenue$—2,302
Operating expenses:Research and development33,80915,565
Operating expenses:General and administrative9,6778,158
Operating expenses:Total operating expenses43,48623,723
Operating expenses:Loss from operations-43,486-21,421
Other income (expense):Change in fair value of warrant liability102
Other income (expense):Change in fair value of term loan-1,470-1,530
Other income (expense):Interest income2,5861,326
Other income (expense):Interest expense-9-19
Other income (expense):Other (income) expense-3113
Other income (expense):Total other income (expense), net1,076-108
Other income (expense):Net loss-42,410-21,529
Other income (expense):Net loss per common share, basic and diluted-0.12-0.08
Other income (expense):Weighted average common shares outstanding, basic and diluted366,632,827269,306,331

Balance Sheet

March 31, 2026 — (in thousands, except share and per share data)

March 31, 2026December 31, 2025
Current assets:Cash and cash equivalents276,576319,767
Current assets:Restricted cash449449
Current assets:Prepaid expenses and other current assets5,2254,431
Current assets:Total current assets282,250324,647
Current assets:Restricted cash2,3152,315
Current assets:Property, plant and equipment, net6,4506,736
Current assets:Operating lease right-of-use assets9,1559,439
Current assets:Other non-current assets181183
Current assets:Total assets300,351343,320
Current liabilities:Accounts payable4,5646,275
Current liabilities:Accrued expenses and other current liabilities15,53420,277
Current liabilities:Total current liabilities20,09826,552
Current liabilities:Term loan, net48,96150,106
Current liabilities:Operating lease liability, net of current portion17,76618,172
Current liabilities:Other non-current liabilities1,5821,552
Current liabilities:Total liabilities88,40796,382
Stockholders’ equityCommon stock, $0.00001 par value per share; 700,000,000 shares authorized and 287,276,885 and 285,051,648 issued and outstanding as of March 31, 2026 and December 31, 2025, respectively33
Stockholders’ equityAdditional paid-in capital964,666958,427
Stockholders’ equityAccumulated other comprehensive income (loss)985-192
Stockholders’ equityAccumulated deficit-753,710-711,300
Stockholders’ equityTotal stockholders’ equity211,944246,938
Stockholders’ equityTotal liabilities and stockholders’ equity300,351343,320
Full release

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as

“anticipates,” “believes,” “expects,” “intends,” “projects,” “plans,” and “future” or similar expressions are intended to identify forward-looking statements.

Forward-looking statements include, but are not limited to, statements concerning the potential of

TSHA-102 and Taysha’s other product candidates to positively impact quality of life and alter the course of disease in the patients Taysha seeks to treat, Taysha’s research, development, regulatory and manufacturing plans for its product candidates, communications with the FDA, including with respect to the BLA for

TSHA-102, the potential for Taysha’s product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies, and whether, if approved, these product candidates will be successfully distributed and marketed and the potential market opportunity for Taysha’s product candidates, and the ability of Taysha’s current cash resources to support planned operating expenses into 2028. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements.

Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding Taysha’s business are described in detail in Taysha’s Securities and Exchange Commission (“SEC”) filings, including in our Annual Report on Form

10-K for the full-year ended December 31, 2025, which are available on the SEC’s website at www.sec.gov. Additional information will be made available in other filings that Taysha makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Taysha disclaims any obligation to update these statements except as may be required by law.

Taysha Gene Therapies, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)

Taysha Gene Therapies, Inc.

Condensed Consolidated Balance Sheet Data

(in thousands, except share and per share data)

Company Contact:

Hayleigh Collins

Senior Director, Corporate Communications and

Investor Relations

Taysha Gene Therapies, Inc. hcollins@tayshagtx.com

Media Contact:

Carolyn Hawley

Inizio Evoke

Carolyn.hawley@inizioevoke.com

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Taysha Gene Therapies earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.